HC Wainwright & Co. Reiterates Buy on Freeline Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a $15 price target.
May 31, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating on Freeline Therapeutics and maintained a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by HC Wainwright & Co. analyst Patrick Trucchio indicates a positive outlook for Freeline Therapeutics. This news is likely to have a positive short-term impact on FRLN's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100